Sofia Lisanti

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.3kcitations56works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell death mechanisms and regulation(17), Parathyroid Disorders and Treatments(17), Oral and gingival health research(14), Chronic Kidney Disease and Diabetes(13), DNA Repair Mechanisms(10)

Publications56 total

Data from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 1 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 5 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 4 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 4 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure Legends from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 5 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 2 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Tables from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure Legends from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 3 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 2 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Data from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Tables from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 1 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Supplementary Figure 3 from Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho
2023Open Access
Data from Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
2023Open Access
Data from Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
2023Open Access
Supplementary Figure 2 from Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
2023Open Access
Supplementary Figure 5 from Chk2 Phosphorylation of Survivin-ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Dario C. Altieri(41), Andrew V. Kossenkov(23), Michele Tavecchio(22), Domenico Delia(22), Jagadish C. Ghosh(21), Valentina Vaira(20), Silvano Bòsari(20), Louise C. Showe(19), Alice Faversani(18), M. Cecilia Caino(17), Alessia Lopergolo(17), Nobuhiko Tanigawa(17), Takehiko Dohi(16), Meenhard Herlyn(15), Ashani T. Weeraratna(15), Reeti Behera(14), Marie R. Webster(14), Abibatou Ndoye(14), Curtis H. Kugel(14), Gretchen M. Alicea(14)